SEC Form 4 · accession 0001104659-18-045813
Voyager Therapeutics, Inc. · VYGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andre Turenne
Officer — President & CEO · Director
Period of report
Jul 16, 2018
Accepted (ET)
Jul 18, 2018 · 5:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640266
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $18.03 | Jul 16, 2018 | A | 650,000 | A | — | Jul 16, 2028 | Common Stock | 650,000 | 650,000 | D |
Explanation of responses
- F1This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The vesting commencement date (the "Vesting Commencement Date") of the option is July 16, 2018. The option vests over four years, with 25% of the shares of common stock underlying the option vesting upon the one-year anniversary of the Vesting Commencement Date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment.